Xiaolin Wang - Mar 17, 2023 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
EVP, Clinical Development
Signature
/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang
Stock symbol
RVMD
Transactions as of
Mar 17, 2023
Transactions value $
-$15,551
Form type
4
Date filed
3/21/2023, 08:32 PM
Previous filing
Mar 3, 2023
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Sale -$15.6K -714 -1.2% $21.78 58.8K Mar 17, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.
F2 This transaction was executed in multiple trades in prices ranging from $21.4075 to $21.784581, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Includes 49,600 RSUs.

Remarks:

EVP, Clinical Development